Renal Impairment Study

AstraZeneca23 enrolled

Overview

The purpose of this study is to see how quickly AZD3355 is taken up in to the blood and leaves the blood in people with normal kidney function or with different degrees of reduced kidney function.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Reflux Renal Excretion

Interventions

AZD3355DRUG

capsule, oral, single dose

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of signed informed consent * Subjects should have either normal renal function or have a moderate renal impairment or severe renal impairment Exclusion Criteria: * History of heart disease * Unstable or clinically significant other disorders such as respiratory, hepatic, metabolic, psychiatric or gastrointestinal disorder

Locations (3)

Research Site

Linköping, Sweden

Research Site

Luleå, Sweden

Research

Uppsala, Sweden

Outcomes

Primary Outcomes

Pharmacokinetic blood samples

Time frame: 15 samples during 0-72 hours

Secondary Outcomes

Pharmacokinetic urine samples

Time frame: 8 samples during 72 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.